VTP 300
Alternative Names: ChAdOx1-HBV; Chimpanzee adenovirus-vectored hepatitis B virus vaccine - Barinthus Biotherapeutics; VTP-300Latest Information Update: 23 Oct 2025
At a glance
- Originator University of Oxford
- Developer Arbutus Biopharma; Barinthus Biotherapeutics
- Class Hepatitis B vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Hepatitis B
Most Recent Events
- 07 May 2025 Immunogenicity and adverse event data from a phase IIa trial in Hepatitis B presented at the European Association for the Study of the Liver Congress 2025
- 07 May 2025 Efficacy and adverse events data from a phase II HBV003 trial in Hepatitis B presented at the European Association for the Study of the Liver Congress 2025 (EASL-2025)
- 07 May 2025 Efficacy data from the phase IIa IM-PROVE II trial in Chronic hepatitis B infection released by Barinthus Biotherapeutics